Ticker Details
Atara Biotherapeutics, Inc. Atara Biotherapeutics Inc is engaged in the development of pharmaceutical products. The company's focus lies on developing therapies addressing serious-life threatening diseases in the United States.
IPO Date:	October 16, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$88.3M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.62 | 3.93%
Avg Daily Range (30 D):	$0.33 | 4.62%
Avg Daily Range (90 D):	$0.28 | 4.73%

Institutional Daily Volume
Avg Daily Volume:	.65M
Avg Daily Volume (30 D):	2.74M
Avg Daily Volume (90 D):	1.16M

Trade Size
Avg Trade Size (Sh.):	131
Avg Trade Size (Sh.) (30 D):	92
Avg Trade Size (Sh.) (90 D):	95

Institutional Trades
Total Institutional Trades:	2,726
Avg Institutional Trade:	$2.22M
Avg Institutional Trade (30 D):	$1.33M
Avg Institutional Trade (90 D):	$1.33M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2M
Avg Closing Trade (30 D):	$4.55M
Avg Closing Trade (90 D):	$4.55M
Avg Closing Volume:	6.14K

News

May 19, 2026 @ 10:22 PM ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, E... Source: Rosen Law Firm

May 18, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Atara Biot... Source: Bronstein, Gewirtz & Grossman Llc

May 14, 2026 @ 6:45 PM DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Off... Source: Law Offices Of Howard G. Smith

May 14, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Atara Biot... Source: Bronstein, Gewirtz & Grossman Llc

May 14, 2026 @ 2:34 AM ATRA Investors Have Opportunity to Lead Atara Biot... Source: The Schall Law Firm

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.76	$-.29	$-.35
Diluted EPS	$-.78	$-.29	$-.36
Revenue	$23.14M	$.52M	$1.6M
Gross Profit
Net Income / Loss	$-9.47M	$-4.15M	$-3.41M
Operating Income / Loss	$-6.31M	$-3.37M	$-2.56M
Cost of Revenue
Net Cash Flow	$-5.51M	$M	$2.74M
PE Ratio

Splits
Jun 20, 2024	1:25